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INTRODUCTION
Breast tumors are frequently detected through physical palpation as a rigid mass residing within the soft normal mammary tissue. The presence of a fibrotic focus in breast tumors is associated with a 10-50-fold increase in tissue stiffness and correlates with distant metastasis and poor outcome. Recent studies indicate that increasing tissue rigidity promotes breast cancer progression, however the underlying molecular mechanism is largely unknown. Breast cancer stem cells have both long-term self-renewal capacity and the ability to initiate tumors. In this proposal, we hypothesize that tissue rigidity regulates breast cancer stem cell properties and function, therefore assisting breast tumor development and promoting chemoresistance. Therefore, the proposed research aims to determine the impact of matrix stiffness on breast cancer stem cell function and to understand the molecular mechanism underlying this regulation. Given the critical role of breast cancer stem cells in breast tumor progression and chemoresistance, our research could lead to novel therapeutics targeting the mechanotransduction pathway to eradicate breast cancer stem cells and overcome chemoresistance.
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ACCOMPLISHMENTS
• What were the major goals of the project?
• What was accomplished under these goals? Task 1. Determine the impact of matrix stiffness on breast cancer stem cell function, Months 1-18:
1. Determine the role of matrix stiffness on regulating breast cancer stem cell properties in 3D mammary culture.
a. Establish the 3D hydrogel culture systems for harvesting large numbers of cells for FACS analysis(Dr. Engler's group).
As reported in the 2014 annual report, Dr. Engler's group has successfully developed the methods to produce two types of hydrogels on which to culture mammary epithelial cells, one with static properties as proposed (polyacrlyamide) and also one with dynamic properties that could remodel with time (hyaluronic acid); the dynamically stiffening material better mirrors the temporal nature of tumor stiffening. Both systems can fully mimic the physiological ranges of tissue rigidities from normal mammary gland (~150Pa) to human breast cancer (~5000Pa). In both systems, matrix stiffness can be accurately defined independently of biochemical factors, such as concentration of ECM proteins and growth factors.
The first system is the 3D PA-Matrigel overlay culture system, where matrix stiffness (or substrate elasticity) is defined by a polyacrylamide (PA) base with calibrated elastic moduli ranging between the ~150 Pascal (Pa) of normal mammary glands and the ~5700 Pa of breast tumor tissues (1, 2) . We fmmd that this 3D PA-Matrigel culture system allows the fmmation of polarized mammary ductal acini in the compliant "soft" mah1x, while rigid matrix stiffuess induced an EMT -like phenotype including loss of epithelial polat1ty, and degradation of basement membrane, and loosening of cell-cell adhesion (Fig. 6D) , consistent with previous publications (1) .
One significant problem with model systems that rely on polyacrylamide and/ or matrigel to recapitulate the mammary niche is that they present constant niche properties to mannnary cells, which is not the case with cancer. Malllillary acini do not develop in a niche with tumorlike stiffuess, e.g. 500-5000 Pa. Rather this stiffening occms after tissue matmation and mamma1y acini formation. mamma1y acinar structme desensitize mammaty epithelial cells to changes in mat11x stiffness?" As described in the 2014 progress repott, to accomplish tllis, we substituted a previously developed hyalmonic acid (HA) hydrogel that was modified with a UV-sensitive methacrylate to petmit "on demand" free radical polymerization (3) . When MCF10A cells were allowed to matme in HA hydrogels with a single round of crosslinking, cells on stiffer mah1ces (3000, and 5000 Pa) undetwent EMT whereas those on soft (100 Pa) did not ( Figure 1 ).
In the past yea1·, we have also continued to develop an understanding of how dynamic matrix changes influence EMT. Previously we showed that a subset of MECs (~25-35%), when grown into acini, were resistant to matt1x stiffening, which would occm dming tumot1genesis. This is unlike what one observes with static and stiff mah1ces, where few cells fail to undergo stiffness-mediated EMT. In this most recent yea1·, we have asked two additional questions: (1) what is the sensitivity of cells to the range of dynamic stiffening from no change to a 30-fold stiffening, and (2) is this response cell autonomous?
When single cells a1·e plated on substi·ates, previous work from Paszek et al (I) identified changes in cells between 400 to 600 Pascals (Pa) of stiffuess. As shown in Figure X , when we stiffen the matrix to 1000 Pa, we still see the majority of cells remaining as acini. Only after 3000 Pa do we see most cells respond. Important with our observations in year 1, we still see 25 b. Use Anchorage-independent mammosphere assay to determine the impact of matrix stiffness on breast CSCmammosphere fomling ability (Dr. Yang' s group) .
As described in the 2014 rep011, we have completed this subaim and found that increasing matrix stiffness significantly increases the mammosphere formation ability in breast cancer cells.
c. Use F ACS analysis of ALDEFLUOR and CSC cell surface markers to test the impact of matrix stiffness on breast CSC propetties (Dr. Yang' s group).
As repmted in the 2014 repmi, we found that CSC cell surface markers CD44 and CD24 and ALDEFLUOR assay were not sufficient to identify cancer stem cell markers in MCF10A cells cultured in vitro. Published literatures show that different cancer stem cells can be emiched with vety diverse members of molecular markers and it is unclear whether any of these markers play a biological role in regulating cancer stem cell function. Therefore, we decided to focus more on using functional assays (including marnmosphere fotmation described in Task 1b above and tumor initiation assay in vivo descti.bed below) to characterize cancer stem cells, instead of relying on molecular markers.
2. Determine whether rigid matrix stiffness promotes tumor initiation efficiency in vivo. For unknown reasons, the USAMRMC Animal Care and Use Review Office (ACURO) did not review our animal protocol submitted in Jan. 2013 until Sept. 2014. After we resubmitted the updated protocol in Sept. 2014 with two follow-up reminders, we fmally received animal protocol approval on Dec. 8, 2014 . Therefore, we started performing the proposed animal experiments only in the past 6 months. Due to our fast progress in Aim 2, we spent more effmis and resources in Aim 2 to perfmm in vitro experiments in the past year.
a. Establish mammaty implantation models and determine the proper dose of BAPN treatment on matrix stiffness in vivo, (Dr. Yang' s group).
Towards this goal, we have implanted EPH4Ras cells in the mammary fat pads and treated half of the mice daily with ~-aminopropionitxi.le (BAPN), a non-reversible LOX inhibitor ( 4, 5) , to inhibit collagen crosslinking. We tested various dose used and the delivety routes (orally through drinking water vs. intx·apeti.toneal injection). In collaboration with Dr. Robert Sah at UCSD Bioengineeti.ng, Dr. Albert Chen in his group has adapted the equipment and analysis software to measure and analyze the elastic modulus of tumor samples by unconfined compression testing (6) . Our prelimimuy data showed that the equilibti.urn elastic modulus of the EPH4Ras tumor samples was in average 800Pa and that BAPN treatment reduced the elastic modulus of EPH4Ras tumor samples by 40% without obvious toxicity (Fig.3A) . To further evaluate whether BAPN reduces fibrillar collagen in hnnors, we used two-photon-excited Second-Hatmonic Generation (SHG) microscopy to image and quantify fibrillar collagen curvarure ratio (7) in unstained tumor sections and confumed the effect of BAPN (Fig. 3B) . Furthennore, BAPN treatxnent resulted in more epithelial tumors with higher Ecadherin expression (Fig. 3C ). We found that intrapeti.toneal injection at a dose of 100 mg/kg in 100 ~tl PBS resulted in the best LOX inhibition A lthough we initially planned to pursue this aim in the 2nd and 3rd year of the :ftmding cycle, we have made vety interesting obsetvations on the role of matrix stiffness in regulating epithelial-mesenchymal transition (EMT) via activating the EMT-inducing transcription factor Twistl soon after star ting this project. Given that the EMT program has been tightly linked to giving rise to breast cancer stem cell properties (8, 9), we have pursued this mechanistic aim immediately ahead of schedule and with much more emphasis given the critical role of EMT in breast cancer progression. EMT-inducing transcription factors blocks the EMT-like phenotype induced by rigid matrix stiffness. There are three major families of EMT -inducing transcription factors, Twistl/2, Snaill/2, and Zebl/2. Based on the availability of shRNAs against these factors, we have tested shRNAs again Twistl and Snail2 to date. We used two independent shRNAs to knock down endogenous Twistl (Fig. 4A ) or Snail2 expression in MCF1 OA and EPH4Ras cells and applied the resulting cells to the 3D mammruy acini cultures with matrix stiffness arrru1ging from 150 Pa to 5700 Pa. Significantly, in both cell types, knockdown ofTwistl, but not Snail2, prevented the EMT-like invasive phenotype induced by the stiff matrix stiffness of 5700Pa; instead these mamma1y cells formed spheroid mrunmruy ductal acini similru· to that in the compliant matrix stiffness of 150Pa ( Fig.4B-4D ). Since high stiffness alone was not sufficient to induce a complete EMT, we further investigated whether Twistl is also required for the induction of a full EMT by mechrurical signals in concert with the EMT-inducing biochemical signal TGF-beta(IO). Indeed, knockdown of Twistl also completely blocked induction of EMT by TGF-beta at high matrix stiffness and rescued acinar development (data not shown). Together, these results indicate that Twist! is a key player in a cellular mechanosensing pathway and plays an essential role in mediating EMT in response to matrix stiffness. To understand the molecular mechanism underlying Twist! cytoplasmic retention, we used mass spectJ:ometry analysis to identify Twistl-binding proteins that anchor Twistl in the cytoplasm. Ras GTPase-activating protein-binding protein 2 (G3BP2) stood out as a promising candidate based on previous studies showing tl1at G3BP2 regulates cytoplasmic retention of MDM2 and IK13a(l 2, 13). We confumed that both endogenously expressed Twist! coimmunoprecipitated with endogenous G3BP2 (Fig. 6A) . Previous studies identified a region of IKBa responsible for binding to G3BP2 (13) . Sequence alignment of this G3BP2-interacting region of IKBa with Twistl and MDM2 revealed a consensus G3BP2-binding motif, (Fig. 6B) . Interestingly, this G3BP2-binding motif is highly conse1ved among vetiebrate Twistl proteins, but to a significantly lesser degree in Drosophila in which Twist expression, rather than localization, is regulated by mechanical cues(ll) (Fig. 6C) . Deletion of tllis motif (~QT mutant) in Twistl abolished its interaction with G3BP2 (Fig. 6D) . Together, these data show that G3BP2 binds to Twistl through the conserved G3BP2-binding motif on vertebrate Twistl proteins. 
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Cl shControl 0 shG3BP2#2 shG3BP2#5 Figure 7 . Loss of G3BP2 cooperates with increasing matrix stiffuess to promote Twist! nuclear localization and EMT. (A) Celllysates fi·om Eph4Ras cells expressing control or G3BP2 sllRNAs were analyzed by SDS-PAGE and probed for G3BP2 and ~-actin. (B) Eph4Ras cells expressing control or G3BP2 sllRNAs were cultured in 3D culture with indicated rigidities for 5 days and stained for Twistl (green) and DAPI (blue). (C) Eph4Ras cells expressing control or G3BP2 sllRNAs were cultured in 3D culture with v&ying rigidities for 5 days and stained for E-cadherin (green), LaJllinin V (red) and DAPI (blue). (D) Quantification of invasive acini in 3D culture described in (C) fi·om 3 independent experiments (P<O.OOl). qPCR analysis of (E) G3BP2, (F) Snail2, (G 9 cytoplasmic retention in compliant matrices. We used shRNAs to knock down G3BP2 expression and determined the impact on Twist1 localization (Fig. 7A, 7E ). For both MCF10A and Eph4Ras cells on compliant matrices, knockdown of G3BP2 resulted in nuclear accumulation of Twist1, suggesting that G3BP2 is necessary for cytoplasmic sequestration of Twist1 in response to low matrix stiffness (Fig. 7B ). These data strongly support a critical role of G3BP2 in regulating Twist1 subcellular localization in response to matrix stiffness.
To test the impact of G3BP2 loss on EMT and invasion, we cultured Eph4Ras and MCF10A cells on a gradient of PA hydrogels with elasticities ranging from 150Pa to 5700Pa in 3D culture. G3BP2 knockdown and the resulting constitutive Twist1 nuclear localization significantly increased the percentage of invasive acini at matrix rigidities ranging from 150Pa to 670Pa ( Fig. 7C and 7D) . Importantly, loss of G3BP2 and increasing matrix stiffness synergistically resulted in destabilization of basement membrane, an EMT phenotype, and invasion of cells into the surrounding ECM ( Fig. 7C and 7D ). The EMT phenotype was characterized by down-regulation of E-cadherin and disruption of basement membrane as shown by Laminin V staining (Fig. 7C) . Furthermore, G3BP2 knockdown repressed expression of Ecadherin and induced expression of Vimentin ( Fig. 7G and 7H ). To determine whether the EMT phenotype resulting from G3BP2 knockdown is dependent on Twist1, we knocked down both Twist1 and G3BP2 and found that the EMT and invasive phenotype were significantly suppressed compared to cells that were only depleted of G3BP2 (Fig. 7I ). Snail2, a direct transcription target of Twist1 (14) , was induced upon G3BP2 knockdown, while double knockdown of G3BP2 and Twist1 blocked Snail2 induction, suggesting that the effects of G3BP2 knockdown are dependent on Twist1 (Fig. 7F ). These data indicate that G3BP2 directly impacts EMT and invasion in response to matrix stiffness and provide a mechanism by which the Twist1-G3BP2 mechanotransduction pathway can facilitate tumor invasion. Furthermore, it suggests that down-regulation of G3BP2 expression in tumor cells could cooperate with increasing matrix stiffness in the tumor microenvironment to facilitate tumor invasion and metastasis.
b. Test whether the EMT program plays a key role in tumor progression in mammary xenografts in response to rigid v.s. compliant matrix stiffness (Dr. Yang's group). We have conducted this subaim ahead of schedule in the past year.
To test the role of G3BP2 in tumor progression in vivo, we employed a human xenograft tumor model of comedo ductal carcinoma in situ, the MCF10DCIS cell line (15) , which is a derivative of MCF10A cells expressing oncogenic Ras. This xenograft model recapitulates the development of ductal carcinoma in situ (DCIS) in human breast cancer. Concordant with our results in Eph4Ras and MCF10A mammary epithelial cells, knockdown of G3BP2 in conjunction with increasing matrix stiffness promoted Twist1 nuclear localization and an invasive phenotype in MCF10DCIS cells in 3D culture, indicating that the Twist1-G3BP2 mechanotransduction pathway is intact in this model (Fig. 8A, 8B ). We injected these cells into the mammary fat pads of NOD/SCID mice and allowed tumor formation for 7 weeks. There was no significant difference in the weight of control and shG3BP2 primary mammary tumors (Fig.  8C) . Immunostaining confirmed significantly lower levels of G3BP2 in tumors with G3BP2 knockdown (Fig. 8D) . Interestingly, in control tumors, αSMA-positive mesenchymal cells were largely present at the edge of the tumor; in contrast, these cells often infiltrated into the intratumoral region in shG3BP2 tumors, a phenotype associated with DCIS to invasive ductal carcinoma progression (Fig. 8D ).
We next examined whether knockdown of G3BP2 affects tumor invasion and metastasis. Tumors expressing G3BP2 shRNAs presented not only local invasion into the sun ounding mammruy tissue, but also regional invasion into the neru·by pe1itoneal wall, visualized as GFP positive tumor cells in these regions ( Fig. 8E and 8F ). More importantly, tumors expressing G3BP2 shRNAs consistently presented with a striking increase in the number of distant metastases in the lungs compared to tumors expressing a control shRNA (mean increase: 15 and 65-fold for shG3BP2#6 and #8 versus control, respectively) ( Fig. 8G, 8H ). Together, these results strongly support a key role for G3BP2 in suppressing invasion and metastasis in vivo.
SUMMARY of RESEARCH ACCOMPLISHMENTS
• We developed two hydrogel systems and determined their mechanic properties.
• We found that increasing tissue rigidities promoted breast cancer stem cell properties.
• We uncovered that a mechanistic link between tissue rigidity and breast cancer stem cells was via the activation of the EMT program.
• We found that the EMT-inducing transcription factor Twist1 was essential for high tissue-rigidity-induced EMT.
• We identified a novel Twist1/G3BP2 mechanotransduction pathway that responds to increasing matrix stiffness in the tumor microenvironment to drive EMT, cancer stem cell properties, invasion, and metastasis.
• What opportunities for training and professional development has the project provided? Nothing to report.
• How were the results disseminated to communities of interest? Dr. Yang has presented this research to three-times breast cancer survivor and donor Vivian Hadge in May 2015.
• What do you plan to do during the next reporting period to accomplish the goals? Plan for the coming year: We plan to continue the study as described in the SOW submitted in the original application. We will specifically focus on the following subaims. a. Test whether Rho-generated cytoskeletal tension is requried for transmitting matrix stiffness to CSC regulation in the 3D PA-Matrigel assays. b. Determine whether any of the inhibitors that are tested positive in a) and b) inhibit CSC-mediated tumor initation in mammary tumor xenografts in vivo. c. Determine whether any of the inhibitors that are tested positive in a) and b) inhibit CSC-mediated chemoresistence in mammary tumor xenografts in vivo.
IMPACT
• What was the impact on the development of the principal discipline(s) of the project? Results from our two years of proposed research have identified a mechanotransduction pathway that transmits the mechanical cues from the breast tumor microenvironment to influence breast cancer stem cell properties via activation of Twist1 and the EMT program. Breast tumors are often detected through physical palpation due to their apparent "hardness" compared to their normal compliant tissues. The presence of a fibrotic focus in breast tumors is a prognostic marker of distant metastasis and correlates with poor survival. Besides the biochemical factors from tumor stroma, fibrotic tumor lesions are associated with a 20-50 fold increase in tissue rigidity. Combining cell and molecular biology techniques with new bioengineering research tools, we have begun to uncover a novel mechanotransduction pathway that link tissue rigidity to breast cancer stem cell function.
• What was the impact on other disciplines? Nothing to report.
• What was the impact on technology transfer? Nothing to report.
• What was the impact on society beyond science and technology? Not only does understanding the impact of tissue rigidity on breast cancer stem cells enhance our knowledge of the molecular regulation of cancer stem cell, it also has direct impact on breast tumor prognosis and cancer treatment. Since cancer stem cells are thought to be responsible for breast tumor initiation and progression, genes and pathways involved in mechanoregulation of cancer stem cells holds promise to be useful prognostic markers for breast cancer. Given the critical role of breast cancer stem cells in breast tumor progression and chemoresistance, our research could lead to novel therapeutics targeting the mechanotransduction pathway to eradicate breast cancer stem cells and overcome chemoresistance.
CHANGES/PROBLEMS
We have published one paper in Nature Cell Biology early this year to report part of the findings of the proposed research. No significant changes in the research proposal, budget, vertebrate animals, and biohazards were made from the original application.
PRODUCTS
• Publications, conference papers, and presentations ! Journal publications: One research article that reports the main funding of the proposed research by both PI and the partnering PI were published in 2015. 
SPECIAL REPORTING REQUIREMENTS
Both PI and the partnering PI will submit the duplicate report. For individual tasks, the contribution from each PI groups is marked. Both groups are located at Univ. of California, San Diego, La Jolla, CA.
APPENDICES:
Two journal publications with the support of this grant are attached.
Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway Matrix stiffness potently regulates cellular behaviour in various biological contexts. In breast tumours, the presence of dense clusters of collagen fibrils indicates increased matrix stiffness and correlates with poor survival. It is unclear how mechanical inputs are transduced into transcriptional outputs to drive tumour progression. Here we report that TWIST1 is an essential mechanomediator that promotes epithelial-mesenchymal transition (EMT) in response to increasing matrix stiffness. High matrix stiffness promotes nuclear translocation of TWIST1 by releasing TWIST1 from its cytoplasmic binding partner G3BP2. Loss of G3BP2 leads to constitutive TWIST1 nuclear localization and synergizes with increasing matrix stiffness to induce EMT and promote tumour invasion and metastasis. In human breast tumours, collagen fibre alignment, a marker of increasing matrix stiffness, and reduced expression of G3BP2 together predict poor survival. Our findings reveal a TWIST1-G3BP2 mechanotransduction pathway that responds to biomechanical signals from the tumour microenvironment to drive EMT, invasion and metastasis.
Breast tumours are often detected by manual palpation, as they are more rigid than their surrounding normal tissue. This increase in tissue rigidity, or matrix stiffness, plays a significant role during tumour progression [1] [2] [3] [4] [5] . Organized collagen fibre alignment, which is a surrogate marker for increasing matrix stiffness in the tumour microenvironment, is associated with breast tumour progression [6] [7] [8] . The importance of mechanical forces in regulating cellular behaviours is also evident during embryogenesis [9] [10] [11] . For example, mesenchymal stem cells undergo lineage selection into either neurons or muscle and bone in response to distinct matrix elasticities 12 . The transcription coactivator YAP accumulates in the nucleus in stiffer matrices to allow osteogenic differentiation of mesenchymal stem cells 13 . How changes in the mechanical properties of extracellular matrix are converted into biochemical and transcriptional responses to direct tumour cell behaviour remains unknown.
Studies have shown that human mammary epithelial cells form normal ductal acini on compliant matrices that recapitulate the stiffness of normal mammary glands. On matrices with increased rigidity similar to breast tumours, however, cells lose apical-basal polarity, form weaker junctions and invade through the basement membrane 1,2 . These cellular changes in response to increasing stiffness resemble many morphological features associated with EMT, a developmental program also critical for tumour cell dissemination and metastasis 14, 15 . During EMT, cells lose their epithelial characteristics, including cell junctions and polarity, and acquire a mesenchymal morphology and the ability to invade. The EMT program is orchestrated through a network of transcription factors, including TWIST1, TWIST2 (refs 16,17) , SNAI1, SNAI2 (refs 18-20) , ZEB1 and ZEB2 (refs 21,22) . Therefore, we set out to understand how matrix stiffness regulates the EMT molecular pathway to promote tumour invasion and metastasis.
RESULTS

TWIST1 is essential for matrix-stiffness-induced EMT and invasion
The basic helix-loop-helix (bHLH) transcription factor, TWIST1, is essential for the ability of tumour cells to metastasize through activation of EMT and extracellular matrix degradation 16, 23 . Mechanical +TGF-β * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * (e) Eph4Ras cells expressing control or Twist1 knockdown shRNAs after 5 days growth in 3D culture on polyacrylamide hydrogels with the indicated rigidities stained for laminin V (red), E-cadherin (green) and nuclei (blue; scale bars, 25 µm). (f,g) Eph4Ras cells expressing control or Twist1 shRNAs were cultured in 3D culture with the indicated rigidities in the absence (f) or presence of 5 ng ml −1 TGF-β (g) for 8 days and stained for E-cadherin (green), fibronectin (red) and nuclei (blue; scale bars, 25 µm). (h-l) qPCR analysis of Twist1 (h), Snai1 (i), Snai2 (j), Zeb1 (k) and Zeb2 (l) mRNA expression in Eph4Ras cells expressing control or Twist1 shRNAs cultured under the indicated matrix rigidities in the absence or presence of 5 ng ml −1 TGF-β ( * , P < 0.05; * * , P < 0.01; unpaired two-tailed t-test with Welch's correction, n = 3 independent experiments, statistics source data can be found in Supplementary Table 1 ; error bars represent s.d.).
forces induce Twist expression during Drosophila larval development 24 ; therefore, we investigated whether increasing matrix stiffness regulates mammalian TWIST1 to promote EMT and tumour invasion. We employed a collagen-coated polyacrylamide hydrogel system with calibrated elastic moduli ranging from the ∼150 pascals (Pa) of normal mammary glands to the ∼5,700 Pa of breast tumour tissues 1, 25 in a three-dimensional (3D) Matrigel overlay culture system [26] [27] [28] . Non-transformed human MCF10A and tumorigenic mouse Eph4Ras mammary epithelial cells were used because unlike normal mammary epithelial cells in vivo 29 , both cell lines endogenously express TWIST1, suggesting that genetic or epigenetic alterations predispose them to tumour progression 23, 30, 31 . Both cells developed polarized ductal acini surrounded by intact basement membrane on compliant 150 Pa matrices. In contrast, at a high matrix stiffness of 5,700 Pa, cells presented a partial EMT phenotype (Fig. 1a) , similar to the matrix-stiffness-induced malignant phenotype described previously 1 . Notably, the intact basement membrane observed at low stiffness was destabilized at high matrix stiffness, consistent with previous observations that increasing matrix stiffness induces cellular invasion 1, 2, 32 ( Supplementary Fig. 1A ). As loss of basement membrane integrity is a critical event during the metastatic cascade, we used this pronounced response as a functional readout of cellular invasion in conjunction with changes in EMT markers.
Using this system, we investigated whether TWIST1 is required for induction of EMT and invasion in response to high matrix stiffness. We generated Eph4Ras and MCF10A cells expressing short hairpin (Fig. le) , demonstrating that matrix-stiffness-induced invasion is Twistl-dependent. As high stiffness alone was not sufficient to induce a complete EMT (Fig. lf) , we investigated whether TWISTl is also required for the induction of a full EMT by mechanical signals in concert with the EMT-inducing biochemical signal TGF-13 (ref. 33) . Consistent with published data 34 , although TGF-13 was not sufficient to induce EMT on soft matrix, rigid matrix together with TGF-13 triggered a complete EMT, evidenced by both immunostaining and quantitative PCR (qPCR) analysis of EMT markers ( Fig. lg and Supplementary Fig. lF,G) . Importantly, knockdown of Twistl completely blocked induction of EMT by TGF-13 at high matrix stiffness and rescued acinar development (Fig. lg) . Together, these data indicate an essential role for TWISTl in mediating matrix-stiffness-induced EMT and invasion.
As the EMT program is orchestrated synergistically by a number ofEMT-inducing transcription factors, we next aimed to understand
hydrogels with the indicated rigidities were analysed by SDS-PAGE and probed for TWIST! and ~-actin. Unprocessed original scans of the blots are shown in Supplementary Fig. 7 . (c-e) Eph4Ras, MCFlOA (c), Bt-549 (d) and MCFlODCIS (e) cells were cultured in 3D cu lture with the ind icated rigidities for 5 days and stained for TWISTl (green) and nuclei (blue; scale bars, 25!lm).
how the EMT transcription program is regulated by matrix stiffness and TGF-f3. The messenger RNA levelsofEMT-inducing transcription factors, Twist 1, Snail, Snail, Zebl and Zeb2 did not change significantly in response to changes in matrix stiffness alone (Fig. lh-1) . On TGF-~ treatment, only Snail rnRNA is markedly induced in a Twistl-independent manner (Fig. li) , as reported previousJT 1 • However, withoutTwistl, TGF-13-induced Snai 1 expression alone could not induce even a partial EMT or any invasive phenotype on soft or hard matrices (Fig. lg) . The mRNA e..-q>ression levels of Snail, Zebl and Zeb2 were significantly dampened on Twist] knockdown (Fig. lj-l) , further supporting a key role of TWlSTl in regulating EMT gene response. These data suggest that TWISTl-dependent mechanotransduction, together with induction of Snail by TGF-13, is required to induce a complete EMT at high matrix stiffness.
Matrix stiffness regulates TWISTl nuclear localization
We next aimed to understand how TWJSTl is regulated by matrix: stiffness to mediate EMT and invasion. As Drosophila Twist mRNA expression is induced by mechanical forces 24 , we examined TWISTl mRNA and protein expression under various matrix rigidities and found no differences (Fig. 2a,b) . Surprisingly, immunostaining showed that TWISTl was largely cytoplasmic on the compliant matri:'C of 150 Pa and ·translocated into tl1e nucleus on the rigid matrix of 
Twist only PLA Nuclei 5,700 Pa. High-stiffness-induced nuclear translocation of TWIST1 was observed in human MCF10A and mouse Eph4Ras cells (Fig. 2c) , and in MCF10DCIS and Bt-549 human breast cancer cells (Fig. 2d,e) , suggesting that nuclear translocation of TWIST1 is a conserved response to increasing matrix stiffness. These results suggest that matrix stiffness could directly impinge on the EMT program by controlling TWIST1 nuclear translocation.
TWIST1 subcellular localization is regulated by a distinct mechanotransduction pathway independent of YAP
We next investigated whether integrin activation is necessary for TWIST1 nuclear localization at high matrix stiffness because mechanosensing responses to matrix stiffness are mediated in part through clustering and activation of integrins 1, 35 . Treatment with a β1-integrin-blocking antibody (AIIB2) prevented nuclear translocation of TWIST1 and blocked the invasive phenotype induced by high matrix stiffness 1,2 ( Fig. 3a) , further supporting a critical role for TWIST1 in mediating matrix-stiffness-induced EMT and invasion. Notably, blockade of β1-integrin activation also prevented nuclear localization of YAP, which was recently identified as one of the few known mechanoresponsive transcription regulators 13 . Therefore, integrin activation is critical to the mechanoregulation of both Twist1 and YAP.
Next we examined whether TWIST1 and YAP are regulated by similar mechanoregulatory machineries. As matrix stiffness also affects 
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a. a. cell shape, we sought to distinguish their impacts on TWIST1 nuclear localization. First, we used micropatterning to selectively alter cell shapes without changing underlying matrix rigidity. Restrictive patterns with areas of 225 µm 2 and 400 µm 2 prevented any cell spreading; in contrast, MCF10A cells on unpatterned regions were able to spread effectively (Fig. 3b) . TWIST1 nuclear localization was not affected by changes in cell shape in either MCF10A or Eph4Ras cells (Fig. 3b-d and Supplementary Fig. 2 ). To confirm that micropatterningrestriction of cell spreading was effective, we also examined the localization of YAP. In contrast to TWIST1, YAP subcellular localization was responsive to changes in cell shape (Fig. 3c,d) , consistent with previous reports that YAP localization is sensitive to any changes in actin cytoskeleton 13, 36 . This difference suggests the existence of distinct mechanoregulatory mechanisms for TWIST1 and YAP. These data also suggest that matrix stiffness directly regulates TWIST1 subcellular localization independently of changes in cell shape.
As TWIST1 protein subcellular localization could be regulated by nuclear transport, we explored whether TWIST1 nuclear import and export might be regulated by matrix stiffness. Treatment of MCF10A cells with leptomycin B, a nuclear export inhibitor 37 , did not promote nuclear accumulation of TWIST1 on compliant matrices (Fig. 3e, upper panel) . In contrast, YAP accumulated into the nucleus on inhibition of nuclear export (Fig. 3e, lower panel) . Therefore, similar to the micropatterning experiment, inhibition of nuclear export differentially affected matrix stiffness regulation of TWIST1 and YAP, supporting the existence of distinct Twist1 and YAP mechanotransduction pathways. Furthermore, as TWIST1 contains two functional nuclear localization sequences 38 , these results suggest that TWIST1 is likely to be actively anchored in the cytoplasm on compliant matrices, therefore preventing nuclear translocation.
Matrix stiffness regulates the interaction between TWIST1 and G3BP2 to control TWIST1 subcellular localization
To understand the molecular mechanism underlying TWIST1 cytoplasmic retention, we used mass spectrometry analysis to identify TWIST1-binding proteins that anchor TWIST1 in the cytoplasm (Supplementary Fig. 3A ). Ras GTPase-activating protein-binding protein 2 (G3BP2) stood out as a promising candidate on the basis of previous studies showing that G3BP2 regulates cytoplasmic retention of MDM2 and NFKBIA (refs 39,40) . We confirmed that both endogenously and exogenously expressed TWIST1 co-immunoprecipitated with endogenous G3BP2 (Fig. 4a and Supplementary Fig. 3C ). Previous studies identified a region of NFKBIA responsible for binding to G3BP2 (ref. 40) . Sequence alignment of this G3BP2-interacting region of NFKBIA with TWIST1 and MDM2 revealed a consensus G3BP2- (Fig. 4b) . Interestingly, this G3BP2-binding motif is highly conserved among vertebrate Twist1 proteins, but to a significantly lesser degree in Drosophila in which Twist expression, rather than localization, is regulated by mechanical cues 24 (Fig. 4c) . Deletion of this motif ( QT mutant) in Twist1 abolished its interaction with G3BP2 (Fig. 4d) . Consistent with its putative role as a cytoplasmic anchoring protein, G3BP2 was observed only in the cytoplasm in Eph4Ras, MCF10A and Bt-549 cells at all matrix rigidities ( Fig. 4e and Supplementary Fig. 3B ). Together, these data show that G3BP2 binds to TWIST1 through the conserved G3BP2-binding motif on vertebrate TWIST1 proteins.
To directly investigate whether matrix stiffness regulates Twist1-G3BP2 interaction, we used an in situ proximity ligation assay (PLA) to examine the interaction of endogenous Twist1 and G3bp2 proteins in 3D acinar cultures of Eph4Ras cells. PLA technology directly detects endogenous Twist1/G3bp2 interactions with high specificity and sensitivity in intact acini using antibodies against Twist1 and G3bp2. Indeed, at 150 Pa a strong PLA signal, indicating Twist1/G3bp2 interaction, was specifically enriched in the cytoplasm. In contrast, very little PLA signal was detected at 5,700 Pa, indicating that Twist1 is released from G3bp2 and translocates into the nucleus at high matrix rigidity (Fig. 4f,g ). To understand whether Twist1-G3bp2 interaction is specifically regulated by matrix stiffness, and not by secondary changes in cell polarity or adherens junctions due to matrix-stiffnessinduced EMT, we examined Twist1-G3bp2 interaction in single cells devoid of apical-basal polarity and mature adherens junctions. PLA analysis in single cells detected strong interaction between G3bp2 and Twist1 in the cytoplasm at low stiffness, but not at high stiffness (Fig. 4h,i) , identical to what we observed in mammary organoids with mature adherens junctions and polarity. These experiments demonstrate that matrix stiffness directly regulates the interaction between Twist1 and G3bp2 to control Twist1 subcellular localization.
Next, we investigated how the interaction between TWIST1 and G3BP2 could be regulated in response to changes in matrix stiffness. Interestingly, the tyrosine residue Tyr 103 (Tyr 107 in murine Twist1), which lies within the identified G3BP2-binding motif of human TWIST1, is predicted as a potential phosphorylation site. This provided a very attractive potential mechanism by which increased matrix stiffness activates integrins and then signals through tyrosine kinases to release TWIST1 from G3BP2. Supportive of this possibility, mass spectrometry analysis of a human lung adenocarcinoma cell line reveals phosphorylation of Tyr 103 on endogenous TWIST1 (ref. 41) , albeit with no known functional consequence. Interestingly, the phospho-deficient Y107F Twist1 mutant co-immunoprecipitated with G3BP2 with similar efficiency as wild-type Twist1 but the interaction between the phospho-mimetic Y107E Twist1 mutant and G3BP2 was markedly attenuated (Fig. 4j) . These data strongly suggest that increasing matrix stiffness could disrupt Twist1-G3BP2 binding through phosphorylation of Tyr 107 within the G3BP2-binding motif of Twist1.
Loss of G3BP2 cooperates with increasing matrix stiffness to promote TWIST1 nuclear localization and EMT
We next investigated whether G3BP2 is functionally required for TWIST1 cytoplasmic retention in compliant matrices. We used shRNAs to knock down G3BP2 expression and determined the impact on TWIST1 localization (Fig. 5a,e, and Supplementary Fig. 4A ). For both MCF10A and Eph4Ras cells on compliant matrices, knockdown of G3BP2 resulted in nuclear accumulation of TWIST1, suggesting that G3BP2 is necessary for cytoplasmic sequestration of TWIST1 in response to low matrix stiffness ( Fig. 5b and Supplementary Fig. 4B ). TWIST1 nuclear localization at high matrix stiffness was not affected by knockdown of G3BP2, consistent with our model in which G3BP2 and TWIST1 dissociate at high matrix stiffness. In further support of distinct mechanoregulation of TWIST1 and YAP, knockdown of G3BP2 did not affect YAP localization (Supplementary Fig. 4D ). These data strongly support a critical role for G3BP2 in regulating TWIST1 subcellular localization in response to matrix stiffness.
To determine the impact of G3BP2 loss on EMT and invasion, we cultured Eph4Ras cells on a gradient of polyacrylamide hydrogels with elasticities ranging from 150 Pa to 5,700 Pa in 3D culture. G3bp2 knockdown and the resulting constitutive Twist1 nuclear localization significantly increased the percentage of invasive acini at matrix rigidities ranging from 150 Pa to 670 Pa. Importantly, loss of G3bp2 and increasing matrix stiffness synergistically resulted in destabilization of basement membrane, an EMT phenotype and invasion of cells into the surrounding ECM (Fig. 5c,d ). The EMT phenotype was characterized by downregulation of E-cadherin and disruption of basement membrane as shown by laminin V staining (Fig. 5c) . Furthermore, G3bp2 knockdown repressed expression of E-cadherin and induced expression of vimentin (Fig. 5g,h ). To determine whether the EMT phenotype resulting from G3bp2 knockdown is dependent on Twist1, we knocked down both Twist1 and G3bp2 and found that the EMT and invasive phenotype were significantly suppressed compared with cells that were depleted of only G3bp2 (Fig. 5i) . Snai2, a direct transcription target of TWIST1 (ref. 42) , was induced following G3bp2 knockdown; in contrast, double knockdown of G3bp2 and Twist1 blocked Snai2 induction, suggesting that the effects of G3bp2 knockdown are dependent on Twist1 (Fig. 5f and Supplementary Fig. 4C ). These data indicate that G3BP2 directly impacts EMT and invasion in response to matrix stiffness and provide a mechanism by which the TWIST1-G3BP2 mechanotransduction pathway can facilitate tumour invasion. Furthermore, they suggest that downregulation of G3BP2 expression in tumour cells could cooperate with increasing matrix stiffness in the tumour microenvironment to facilitate tumour invasion and metastasis.
Loss of G3BP2 promotes tumour invasion and metastasis in vivo
To investigate the role of G3BP2 in tumour progression in vivo, we employed a human xenograft tumour model of comedo ductal carcinoma in situ, the MCF10DCIS cell line 43 , which is a derivative of MCF10A cells expressing oncogenic Ras. This xenograft model reca-pitulates the development of ductal carcinoma in situ (DCIS) in human breast cancer. Concordant with our results in Eph4Ras and MCF10A mammary epithelial cells, knockdown of G3BP2 in conjunction with increasing matrix stiffness promoted TWIST1 nuclear localization and an invasive phenotype in MCF10DCIS cells in 3D culture, indicating that the TWIST1-G3BP2 mechanotransduction pathway is intact in this model (Fig. 6a,b, and Supplementary Fig. 5 ). We injected these cells into the mammary fat pads of NOD/SCID mice and allowed tumour formation for 7 weeks. There was no significant difference in the weight of control and G3BP2 shRNA primary mammary tumours (Fig. 6c) . Immunostaining confirmed significantly lower levels of G3BP2 in tumours with G3BP2 knockdown (Fig. 6d) . Interestingly, in control tumours, αSMA-positive mesenchymal cells were largely present at the edge of the tumour; in contrast, these cells often infiltrated into the intratumoral region in G3BP2 shRNA tumours, a phenotype associated with the progression of DCIS to invasive ductal carcinoma (Fig. 6d) .
We next examined whether knockdown of G3BP2 affects tumour invasion and metastasis. Tumours expressing G3BP2 shRNAs presented not only local invasion into the surrounding mammary tissue, but also regional invasion into the nearby peritoneal wall, visualized as GFP-positive tumour cells in these regions (Fig. 6e,f) . More importantly, tumours expressing G3BP2 shRNAs consistently presented with a striking increase in the number of distant metastases in the lungs compared with tumours expressing a control shRNA (mean increase: 15-and 65-fold for G3BP2 shRNA6 and shRNA8 versus control, respectively; Fig. 6g,h ). Together, these results strongly support a key role for G3BP2 in suppressing tumour invasion and metastasis in vivo.
Downregulation of G3BP2 and increasing collagen organization synergistically predict poor outcome in breast cancer patients
We next investigated whether the TWIST1-G3BP2 mechanotransduction pathway has a significant role in human cancer progression. We first analysed The Cancer Genome Atlas (TCGA) breast cancer (TCGA_BRCA_G4502A_07_3) data set and observed a decrease in overall survival in patients with tumours with low G3BP2 expression ( Supplementary Fig. 6A,B) . Furthermore, consistent with a role in preventing EMT and invasion, we observed that G3BP2 protein expression was restricted to the luminal epithelial cells in normal human breast and colon tissues ( Fig. 7a and Supplementary Fig. 6D ). We next analysed G3BP2 expression and collagen organization in a cohort of 152 stage-3 breast tumours from the NCI Cancer Diagnosis Program (Fig. 7b) . We analysed collagen fibre alignment by second harmonic generation imaging (SHG) and used it as a surrogate marker for tissue rigidity. In agreement with previous publications [6] [7] [8] 44, 45 , stage-3 patients presenting stiffer tumours (organized collagen structures) had a median recurrence-free survival time of 31 months compared with 49 months in patients with more compliant tumours (disorganized collagen; P = 0.0014; Supplementary Fig. 6C) . Importantly, the level of G3BP2 expression, together with matrix stiffness, could further stratify these patients to predict outcome (Fig. 7c) . Patients with disorganized collagen/G3BP2 high tumours had markedly improved outcomes with a 10-year recurrence-free survival rate of 46.4% compared with 10.1% of patients with organized collagen/G3BP2 low tumours. Patients whose tumours presented either low G3BP2 or organized collagen fibres had intermediate survival outcomes (31.18% and 33.33% 10-year recurrence-free survival, P = 0.0284), reflective of the cooperative effect of G3BP2 loss and increasing matrix stiffness on tumour progression. The association between downregulation of G3BP2 and poor prognosis was independent of tumour grade or oestrogen receptor status ( Supplementary Fig. 6E,F) . Concordant with data from 3D culture and animal tumour models, these results demonstrate that increasing rigidity in the tumour microenvironment, in concert with downregulation of G3BP2, promotes human breast tumour progression.
DISCUSSION
In summary, we demonstrate that increasing matrix stiffness in the tumour microenvironment directly activates EMT, tumour invasion, and metastasis through the EMT-inducing transcription factor TWIST1. This mechanotransduction pathway may have important implications in breast tumours, as G3BP2 loss and tissue rigidity act synergistically to promote tumour progression. Given that matrix stiffening and ECM reorganization has been observed in many human tumour types 10 , the Twist1-G3BP2 mechanotransduction pathway warrants further investigation as a key mode of EMT activation as well as for therapeutic applications.
Mechanistically, our study reveals a molecular pathway directly linking mechanical forces with transcriptional regulation of the EMT program. Our findings suggest a model in which increasing matrix stiffness induces integrin-dependent phosphorylation events and release of TWIST1 from its cytoplasmic anchor G3BP2 to enter the nucleus and drive transcriptional events of EMT and invasion. Notably, to our knowledge, low stiffness and integrin disengagement are the only conditions in which cytoplasmic retention of TWIST1 are observed, thus providing a unique mode of EMT regulation 46 . Interestingly, our analyses showed that matrix stiffness regulates TWIST1 and YAP/TAZ through distinct molecular mechanisms, suggesting that multiple mechanotransduction pathways exist. We found that the TWIST1-G3BP2 signalling axis is responsive only to matrix stiffness and is independent of cell shape, cell polarity and adherens junction; in contrast, YAP/TAZ are sensitive to all of these factors. At present, the complete molecular pathways that transmit the mechanical signals from extracellular matrix to either the YAP/TAZ or TWIST1 signalling axis remain to be elucidated. Understanding the similarities and differences between the YAP/TAZ versus TWIST1 mechanotransduction pathways will provide further insight into how different mechanical cues are interpreted into unique biological responses. Given the importance of mechanoregulation in embryonic morphogenesis, such information would have broad implications not only in tumour progression, but also in development.
METHODS
Methods and any associated references are available in the online version of the paper. 
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METHODS
Cell culture. MCF10A cells were grown in DMEM/F12 media supplemented with 5% horse serum, 20 ng ml −1 human EGF, 10 µg ml −1 insulin, 0.5 µg ml −1 hydrocortisone, penicillin, streptomycin and 100 ng ml −1 cholera toxin (SigmaAldrich). Eph4Ras cells were cultured as previously described in MEGM (Lonza) mixed 1:1 with DMEM/F12 media supplemented with 10 ng ml −1 human EGF, 10 µg ml −1 insulin, 0.5 µg ml −1 hydrocortisone, penicillin and streptomycin 23 . Bt-549 cells were grown in RPMI 1640 supplemented with L-glutamine, penicillin, streptomycin, 10% fetal bovine serum and 1 µg ml −1 insulin. All cell lines were tested for mycoplasma contamination.
Generation of stable knockdown cell lines. Stable gene knockdown cell lines
were generated using lentiviral plasmid vectors. Briefly, shRNA target constructs were introduced by infection with lentiviruses. Concentrated viral supernatants were applied to target cells with 6 µg ml −1 protamine sulphate. Infected cells were then selected for with 2 µg ml −1 puromycin or blasticidin.
Polyacrylamide hydrogel preparation. Hydrogels were prepared as previously described on No. 1 12 mm and 25 mm coverslips 47 . Briefly, No. 1 glass coverslips were etched using 0.1 N NaOH, functionalized using 3-aminopropyltriethoxysilane (Sigma-Aldrich), rinsed with dH 2 O, incubated in 0.5% glutaraldehyde in PBS, dried, and then acrylamide/bis-acrylamide mixtures polymerized between the functionalized coverslip and a glass slide coated w th dichlorodimethylsiloxane (Sigma-Aldrich). Polyacrylamide-coated coverslips were then washed twice with dH 2 O, incubated with 1 mM Sulpho-SANPAH (Thermo Scientific Pierce) in HEPES buffer under 365 nm ultraviolet light for 10 min, rinsed twice with 50 mM HEPES pH 8.5 buffer, incubated at 37 • C overnight with rat tail Collagen I (Millipore) in 50 mM HEPES pH 8.5 buffer, rinsed twice in 50 mM HEPES pH 8.5 buffer, and sterilized.
Three-dimensional (3D) cell culture. MCF10A and Eph4Ras cells were grown in 3D cell culture as previously described 28 . Briefly, Eph4Ras cells were seeded on hydrogels in 2% Matrigel (BD Biosciences) MEGM mixed 1:1 with DMEM/F12 and MCF10A cells seeded similarly in 2% Matrigel DMEM/F12 media supplemented with 2% horse serum, 5 ng ml −1 human EGF, 10 µg ml −1 insulin, 0.5 µg ml −1 hydrocortisone, penicillin, streptomycin and 100 ng ml −1 cholera toxin.
3D confocal microscopy.
We used a protocol adapted from the method described in ref. 28 . In brief, cells were fixed with 2% paraformaldehyde (PFA) for 20 min at room temperature, permeabilized with PBS-0.5% Triton X-100, quenched with 100 mM PBS-glycine, and then blocked with 20% goat serum-immunofluorescence (IF) buffer (130 mM NaCl, 7.7 mM NaN 3 , 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20, PBS). Samples were incubated with primary antibodies overnight in 20% goat serum-IF buffer, washed 3 times with IF buffer, incubated w th secondary antibodies for 1 h, washed 3 times with IF buffer, counterstained for nuclear for 15 min (5 ng ml −1 DAPI or TO-PRO-3), washed once with PBS, and mounted with Slow Fade Gold (Invitrogen). Confocal images were acquired using an Olympus FV1000 with 405, 488, 555 and 647 laser lines. Images were linearly analysed and pseudo-coloured using ImageJ analysis software.
Invasive acini quantification. Invasive acini were quantified using bright-field images with a minimum of 5 random low-magnification fields being analysed per condition per experiment. Acini were scored as either normally developed acini or acini that adopted a spread and invasive phenotype.
Second harmonic generation microscopy. Formalin-fixed paraffin embedded sections (5 µm) were re-hydrated and imaged using a multi-photon Leica SP5 confocal microscope using a Ti:sapphire light source and a ×20 water-immersion objective at 880 nm. Fields were acquired using resonant scanning mode, line averaging, and frame accrual. IF staining was sequentially imaged using scanning laser confocal microscopy. The scoring rubric (which was defined before blinded scoring) for SHG analysis was defined as 'organized collagen' in tumours having prominent linearized collagen fibres (with a circularity close to 0) or as 'disorganized collagen' in tumours having e ther collagen fibres with a high degree of circularity (that is, curved) or low/no SHG signal.
Tumour tissue microarrays. National Cancer Institute Cancer Diagnosis Program
stage-3 breast cancer progression tumour tissue microarrays (TMA) were stained for G3BP2 by immunofluorescence for retrospective analysis. TMAs were concurrently imaged by confocal microscopy and SHG. Cores that were missing, damaged, or without detectable tumour cells were omitted from analyses. G3BP2 was scored blindly according to the following rubrics. G3BP2 expression was scored 0 for no detectable expression, 1 for very weak expression, 2 for moderate expression in greater than 75% of tumour cells, and 3+ for strong expression in greater than 75% Immunoprecipitation. Cells were lysed using a 2-step protocol adapted from ref. 48 . Cells were directly lysed with lysis buffer (20 mM Tris-HCl, 1% Triton X-100, 10 mM MgCl 2 , 10 mM KCl, 2 mM EDTA, 1 mM NaF, 1 mM sodium orthovanadate, 2.5 mM β-glycerophosphate, 10% glycerol, pH 7.5), scraped off the culture dish, sonicated, supplemented to 400 mM NaCl, sonicated and diluted to 200 mM NaCl. Antibodies were conjugated to protein G beads (Invitrogen), crosslinked using disuccinimidyl suberate (Thermo Scientific Pierce) as per the manufacturer's protocol, incubated with lysates overnight at 4 • C, washed eight times with IP lysis buffer supplemented with 200 mM NaCl, and eluted using 50 mM DTT LDS sample buffer at 95 • C for 15 min. 5B7 mouse hybridoma concentrated supernatant was used. For immunoprecipitation of exogenously transfected Myc-Twist1, 293T cell lysates were collected 48 h after transfection and subjected to the 2-step lysis protocol. Immunoprecipitation was performed using anti-Myc antibody (9E10) crosslinked to protein A agarose beads (Invitrogen).
Mass spectrometry. The gel bands were excised and cut into 1 × 1-mm pieces. In gel digestion and extraction were done as previously described 49 . The peptides were separated on a reversed-phase HPLC analytical column (360 µm O.D. × 50 µm I.D., ODS-AQ 5 µm, 10 cm) with an integrated tip (1-2 µm) with a gradient of 0-40%B for 30 min, 40-100%B for 5 min, 100%-0%B for 2 min, and 0%B for 15 min using an Agilent 1100 quaternary pump and eluted into an LTQ Orbitrap. The LTQ Orbitrap was operated in a data-dependent mode. MS spectra were acquired in the Orbitrap w th a resolution of 15,000 and MS/MS spectra were acquired in the LTQ. Tandem mass spectra were searched against the IPI mouse database using Bioworks with the following modification: differential Methionine 15.9949. For peptides an xcorr cutoff filter of 1.5 for +1, 2.0 for +2 and 2.5 for +3 was applied, and identified peptides were confirmed by manually inspecting the MS/MS spectra.
Micropatterning. Micropatterned coverslips were designed with and produced by CYTOO (http://www.cytoo.com). Square micropatterns were produced in blocks w th a 90 µm pitch between each pattern with a block period of 1,300 µm. Each pattern block was produced in duplicate on each coverslip. Activated coverslips were coated w th 20 µg ml −1 rat tail collagen I for 2 h at room temperature. Cells were then seeded for 6 h and then fixed for analysis by confocal microscopy. At least 25 random single cells from 5 random fields were analysed per condition.
Motif sequence alignment. Sequences were aligned using ExPASy SIB bioinformatics portal 50 .
Proximity ligation assay. Cells were 3D cultured on polyacrylamide gels for 20 h or 6 days and fixed and processed as described for immunofluorescence before performing Duolink PLA (Sigma-Aldrich) as per the manufacturer's protocol. Briefly, mouse anti-Twist1 (Abcam, ab50887, Twist2C1a, 1:150) and rabbit anti-G3BP2 (Sigma-Aldrich, HPA018425, 1:600) primary antibodies were used to detect endogenous proteins and subsequently recognized using species-specific plus and minus PLA oligonucleotide-conjugated probes at 37 • C for 60 min. Interacting probes were then ligated at 37 • C for 30 min and detected by polymerase-mediated amplification at 37 • C for 100 min and subsequently analysed by fluorescent confocal microscopy. For analysis of formed day 6 acini a minimum of 50 cells from 5 random fields were quantified per condition. For analysis of single cells seeded for 20 h a minimum of 25 cells from 5 random fields were quantified per cond tion. To quantify the PLA signal, confocal images were thresholded using ImageJ analysis software. The area with positive PLA signals was then quantified and divided by the number of cells examined.
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Xenograft tumour assay. All animal care and experiments were approved by the Institutional Animal Care and Use Committee of the Univers ty of California, San Diego. MCF10DCIS cells (1.0 × 10 6 ) suspended in 15 µl Matrigel (BD Biosciences) were injected bilaterally into the inguinal mammary fat pads of 8-week-old female SCID-beige mice. No statistical method was used to predetermine sample size and the experiments were not randomized. Mice were euthanized and tumour burden was analysed at 7 weeks post tumour implantation. Mice were dissected and tumour invasion was assessed in situ using a fluorescent dissection scope (Leica Microsystems). The investigators were not blinded to allocation during experiments and outcome assessment. All work with animals was performed in accordance with UC San Diego IACUC and AAALAC guidelines.
TCGA data set analysis. The TCGA breast cancer gene expression data set (TCGA BRCA G4502A_07_3) was downloaded from the UCSC Cancer Genome Browser (https://genome-cancer.ucsc.edu). Samples were stratified by G3BP2 expression, with G3BP2 high and G3BP2 low samples with expression above and below mean G3BP2 expression, respectively. Overall patient survival in each group was then analysed.
Statistical analysis.
All P values were derived from Student's t-test using unpaired two-tailed analysis with Welch's correction, unless otherwise noted. Error bars denote standard deviation unless otherwise noted. Kaplan-Meier survival curves were analysed by Cox-Mantel Log-rank analysis. Contingency tables were analysed using Fisher's exact analysis. Statistical significance was defined as P < 0.05, with regard to the null hypothesis. All qualitative data shown using representative data were repeated in at least 3 independent experiments.
Real-time PCR. RNA was extracted from cells using the RNeasy Mini and Micro Kit (Qiagen). cDNA was generated using random hexamer primers and a cDNA Reverse Transcription Kit (Applied Biosystems). Expression values were generated using ddCt values normalized to GAPDH. Experiments were performed in biological and technical triplicate using 7500 Fast (Applied Biosystems) and CFX Connect (Bio-Rad) real-time PCR detection systems. For data analysis in each comparison (one shRNA versus the control shRNA), unpaired two-tailed Student's t-tests with Welch's correction were used to determine statistical significance. Shared murine and human primer sequences: GAPDH (5 -GACCCCTTCATT GACCTCAAC-3 , 5 -CTTCTCCATGGTGGTGAAGA-3 ).
shRNA sequences. pSP108 lentiviral target sequences: Twist1 shRNA3, 5 -AAGC TGAGCAAGATTCAGACC-3 . Twist1 shRNA5, 5 -AGGTACATCGACTTCCTG TAC-3 . ControlshRNA (GFPshRNA), 5 -GCAAGCTGACCCTGAAG-3 .
pLKO.1 (Sigma-Aldrich) lentiviral target sequences: G3BP2shRNA2, 5 -AGT TAAATTGAGGTGGACATT-3 . G3BP2shRNA5, 5 -TTCGAGGAGAAGTAC GTTTAA-3 . G3BP2shRNA6, 5 -CGGGAGTTTGTGAGGCAATAT-3 . G3BP2 shRNA8, 5 -CCACAAAGTATTATCTCTGAA-3 . ... . . . -.. . 
Abstract
During tumor development, tumor cells constantly commu nicate with the surrounding microenvironment through both biochemical and biophysical cues. In particular, the tumor micro environme nt ca n instruct ca rcinoma cells to undergo a morpho genesis program termed epithelial to mesenchymal transition (EMT) to faci litate local invasio n and metastatic dissemination. Growi ng evidence uncovered a plethora of microenvironmental factors in promot ing EMf, including proinflammatory cytokines secreted by locally activated stromal cells, hypoxia conditions, extracellular matrix components, and mechanical properties. Here, we review various biochemical and biophysical factors in
Background
Owing tumor metastasis, the epithelial to mesenchymal tran sition (EMT) program has been indicated in giving rise to the dissemination of single tumor cells from primary epithelia! tumors (1) . EMT refers to a global cellular and molecular tran sition by which polarized epithelial cells gain mesenchyma! properties to migrate. During EMT, epithelial cells reorganize cytoskeleton and resolve cell cell junctions, which are accompa nied with switching off the expression of epithelial markers and turning on mesenchymal genes. Although changes in epithelial and mesenchymal markers during EMT can vary significantly in different biologic contexts, a network of transcription factors, including 1WIST1f2, SNAILl/2, ZEBl/2, and FOXC2, are consis tently required to orchestrate the EMT program (2) . Numerous studies have shown that the expression of these transcription factors is associated with poor prognosis and distant metastasis in various human cancers (3). Besides its role in promoting tumor cell invasion, EMT is shown to confer tumor cells with resistance to apoptosis ( 4) and anoikis (5), thus allowing cell survival in the blood stream after intravasation. EMT could also facilitate tumor cells' escape from the senescence program, especially through 1WIST1 and ZEB1 (6, 7). Furthermore. EMT has been shown to 1 endow cancer cells with cancer stem cell (CSC) like features, which further aid tumor dormancy and chemoresistance (8, 9) .
Studies with tumor samples or experimental tumor xenograft models have provided convincing evidence for the activation of EMT in various primary epithelial tumors. Interestingly, more recent studies reveal a dynamic requirement of EMT in tumor metastasis: activation of EMT promotes local tumor invasion, intravasation, and extravasation of the systemic circulation, whereas reversion of EMT is essential to establish macrometas tases in distant organs (1, 10) . The 'reversible' EMT model implies that EMT is unlikely to be regulated by permanent genetic and epigenetic changes in tumor cells; instead, EMT is dynami cally controlled by various proinvasion signals from the tumor microenvironment (TME!).
The TME is defined as the cellular and physical environment surrounding the primary tumor including endothelial, inflam matory and immune cells, fibroblasts, extracellular matrix (ECM) components, and soluble factors. In this review, we discuss the most relevant and direct connections between TME signals and the EMT inducing uanscription factors in cancer. On the basis of the properties of the TME signals, we divide our discussion into fow major categories: inflammatory signals, hypoxia, ECM com ponents, and ECM mechanical properties (Fig. 1) .
Inflammatory cytokines
An association between cancer development and inflammation has long been observed. During tumor progression, tumor cells recruit activated fibroblasts and immune cells that in tum secrete manycytokinestoaffect tumor development and metastasis (11 
Hypoxia
Hypoxia condition has been shown to select tumor cells to become more invasive and metastatic. Specifically, hypoxia can promote EMT via hypoxia inducible factor 1a (HIF1a; ref. 22) . HIF1a is found to increase SNAIL1 protein stability, leading to suppression of E cadherin in ovarian carcinoma (23) . Yang and colleagues (24) found that HIF1a could induce TWIST1 expres sion by binding directly to the TWIST1 promoter. In addition, HIF1a cooperates with inflammatory cytokines to promote EMT. For example, HIF1a, together with TGFb, promotes SNAIL1 nuclear translocation to induce EMT through the suppression of estrogen receptor b in prostate carcinoma (25) . Also, HIF1a could enhance the expression of TWIST1 by upregulating TNFa, IL6, and TGFb in prostate cancer (26) . Hypoxia, together with the Wnt/ b catenin signaling, can also promote SNAIL1 stability by inhibit ing GSK3b (27) . Taken together, HIF1a, often in cooperation with additional TME factors, can induce EMT, suggesting a promising strategy to target hypoxic signaling for cancer therapeutics.
ECM components
ECM includes structural and nonstructural components that can activate cellular signaling through membrane bound recep tors such as integrins. The critical role of ECM in promoting EMT was already evident in the original experiments conducted by Greenburg and Hay (28) . They showed that epithelial cells from embryonic and adult anterior lens cultured in three dimen sional collagen gels can elongate and migrate as individual cells. Indeed, Greenburg and Hay (28) concluded that "interactions with ECM may be a major factor in the ability of a cell to become mesenchymal."
Recently, Zhang and colleagues (29) unraveled a direct con nection between ECM structural protein collagen I and SNAIL1. They found that collagen I binds to its receptor DDR2 and activates downstream SRC/ERK2 to stabilize SNAIL1 in breast tumors cells. SNAIL1 further upregulates MT1 MMP and collagen I to promote tumor cell invasion. Another ECM structural com ponent, fibronectin, partly through binding to integrin receptors, induces SNAIL1 expression in tumor cells. This study demon strated that cooperation of fibronectin and TGFb was required to activate the downstream SRC and ERK/MAPK kinases and induce EMT (30) . Hyaluronan (HA) is a major component of ECM and signals through its membrane receptor CD44, which is over expressed in many human cancers. HA binding to tumor cells was found to induce CD44 nuclear translocation and activate LOX expression, which in turn upregulates TWIST1 expression to promote breast cancer metastasis (31) . Periostin, a nonstructural ECM component highly expressed in human tumors, could signal through integrins to increase cell survival and promote metastatic progression of colon cancer in vivo (32). Kim and colleagues (33) identified differential roles of periostin in EMT: it induces SNAIL1 expression in prostate cancer cells, whereas it inhibits TWIST1 expression in bladder cancer cells. These studies show that many ECM components are key regulators of EMT and tumor invasion.
ECM mechanical properties
During tumor progression, ECM is constantly remodeled by various cell types in the TME. Specifically, increasing matrix stiffness through LOX mediated collagen cross linking plays a critical role in tumor invasion and metastasis. Pioneer study by Paszek and colleagues (34) showed that increasing ECM stiffness induced a malignant phenotype, associated with activated FAK and ERK signaling. LOX mediated ECM stiffening promoted tumor progression in vivo partially via an activated FAK signaling (35) . Conversely, treatment with a LOX inhibitor reduced focal adhesions and PI3K signaling, demonstrating that LOX modu lates tumor progression through ECM stiffening to drive focal adhesion assembly. Furthermore, ECM stiffening was required to corporate with TGFb to induce EMT in human breast tumor cells (36) , further strengthening the notion that mechanical properties of the tumor microenvironment are key factors regulating EMT and promoting tumor progression.
Clinical-Translational Advances
Accumulating evidence supports a critical role of EMT in many aspects of tumor development, including resistance to apoptosis and senescence, CSCs, and invasion and metastasis, thus suggest ing that targeting this process could be a promising therapeutic approach. However, the core EMT transcription factors remain technically challenging to target. Instead, a number of preclinical studies suggest that inhibiting EMT inducing TME signals could serve as alternative approaches to impinge upon the EMT pro gram. Here, we summarize therapeutics in preclinical and clinical studies that target TME to prevent tumor progression (Table 1) .
Inflammatory cytokines
Preclinical studies support the importance of inflammatory cytokines, including TNFa and IL6, in promoting EMT and tumor invasion. Several TNFa inhibitors have been tested in clinical trial in different types of cancers. For example, infliximab, a TNFa monoclonal blocking antibody, has been tested in phase II clinical trials in renal cell carcinoma and advanced cancers (37, 38) . These studies suggested that TNFa inhibitor was effective to suppress the levels of IL6 and CCL2 in patients and improved progress free survival. Two clinical studies examined the therapeutic effects of etanercept, a TNFa antagonist, in recurrent ovarian cancer and metastatic breast cancer. Etanercept is well tolerated in patients and significantly improved progress free survival with consistent decrease in CCL and IL levels (39, 40 suppress tumor progression and metastasis. Bortezomib, a pro teasome inhibitor that suppresses NFkB activation, was tested in phase II clinical studies with metastatic gastric adenocarcinoma, and recurrent and metastatic head and neck squamous cell car cinoma (41, 42) . Although bortezomib alone showed poor response in patients, combination therapy with docetaxel or targeted inhibition of other oncogenic pathways are currently under way in solid tumors. Finally, various blocking antibodies against cytokines have been used in various clinical studies. CNTO 328, an IL6 ligand blocking antibody, was tested in phase I/II clinical trials for the treatment of metastatic renal cell carci noma. This study showed that CNTO 328 could increase patient survival and more than 50% of progressive metastatic renal cell carcinoma patients presented stable diseases upon treatment (43) . Together, these clinical trials in progress could bring a number of promising anti inflammatory cytokine agents to the forefront of antimetastasis therapeutics.
The TGFb signaling is extensively targeted to block tumor progression and metastasis, and various approaches have been taken to inhibit the TGFb signaling. AP 12009, an antisense oligonucleotide against TGFbII, was tested in patients with high grade glioma and significantly improved survival compared with standard chemotherapy treatment (44) . Furthermore, TGFb neutralizing antibody GC 1008 showed promises in phase I trial for metastatic melanoma and renal cell carcinoma (45) . Small molecule inhibitor, LY 573636, used in phase II clinical studies in patients with metastatic NSCLC, soft tissue sarcoma, and mela noma, has also shown modest activity as a second/third line therapy (46 48 ). These studies showed that inhibiting TGFb signaling pathway is safe, well tolerated in patients and could provide promising new therapeutics against tumor invasion.
Hypoxia
Several HIF1a inhibitors have also shown remarkable antitu mor activities in a variety of preclinical and clinical trials. EZN 2698, an antisense oligonucleotide against of HIF1a, is being tested in a phase I clinical trial with advanced solid tumors (49) . Another HIF1a inhibitor, PX 478, which inhibit HIF1a expres sion, is currently tested in phase I clinical trials in patients with advanced metastatic cancer (49) . Several novel compounds have also been identified in a high throughput screen using a cell based reporter of HIF1a transcriptional activity. One such compound topotecan has been tested in phase I/II clinical trials with con ventional chemotherapies such as cisplatin or bevacizumab in patients with advanced lung cancer. Clinical results indicate that combination treatment is well tolerated and worthy of further clinical investigation (50), thus making them promising agents against tumor metastasis.
ECM components
Disruption of tumor ECM integrity has shown promising results in halting tumor metastasis in preclinical studies. Methy lumbelliferone, a HA synthesis inhibitor, was effective in prevent ing bone metastasis of lung cancer in vivo (51) . Neutralizing antibody directed against periostin resulted in 40% inhibition of tumor growth (P < 0.001), 80% inhibition of lung metastasis (P < 0.001), and significant increase in survival (P < 0.05) using mouse breast tumor xenografts (52) .
Because cells that have undergone EMT secrete many unique ECM components, these ECM molecules have also been used for targeting drug delivery to tumors. For example, a promising approach has been used in clinical trials for patients with glio blastoma multiforme (GBM), linking anti Tenascin C antibody to radioactive particles to specifically target tumor cells. Result showed minimal toxicity associated with a promising antitumor benefit and encouraging overall outcomes (53) . Recently, engi neered HA based conjugates have emerged as a promising strategy to efficiently target tumors with drugs exerting poor solubility and strong side effects, such as paclitaxel (54) . These strategies take advantage of unique EMT associated TME components to achieve targeted delivery of traditional chemotherapeutics, thus present ing a new anticancer therapeutic strategy.
ECM mechanical properties
In patients, the presence of fibrotic foci in breast tumors is a prognostic marker of distant metastasis and correlates with poor survival (55) . In addition, LOX is essential for hypoxia induced breast cancer metastasis and its expression in patients is correlated to a poor outcome (56) . Finally, a recent study shows that LOX is critical to establish a permissive microenvironment within fibrotic tissues, characterized by increased EMT, to favor the colonization of metastasizing tumor cells (57) . Thus, anti LOX strategies could suppress metastatic progression of the disease, not only by target ing the TME of the premetastatic niche, but also by targeting tumor cells themselves, as shown by the direct effect of LOX inhibition in attenuating FAK dependent breast cancer cell invasion in a pre clinical study (58) . Therapeutic inhibition of FAK, recently vali dated in a phase I study, may also be a promising approach to prevent the effect of TME stiffness on metastatic progression of several types of cancer. Indeed the use of pharmacologic inhibitor PF 00562271 in patients with advanced solid tumors unrespon sive to existing therapies showed a significant stabilization of the disease, thus supporting FAK as a potential therapeutic target (59).
Conclusion and Discussion
As discussed, a number of inhibitors targeting TME are being tested in preclinical and clinical trials and well tolerated in patients and several showed promising results. Because these TME signals regulate various signaling pathways, the impacts of these inhibitors on tumor progression are likely beyond the EMT program. Given the critical role of EMT in multiple steps of tumor progression, targeting the EMT inducing TME signals is indeed worth pursuing to combat metastatic cancers.
However, there are also a number of issues to be resolved to better decide how to effectively affect tumor progression by targeting the EMT program. First, current clinical trials largely aim to shrink established metastases, in which the EMT program may not be involved. Instead, metastasis prevention trials in patients with cancer with high metastasis risk would be the appropriate setting to test the effect of EMT inhibition on metas tasis occurrence. Second, recent studies demonstrated the dynam ic involvement of EMT in tumor metastasis: activation of EMT promotes tumor dissemination and reversion of EMT is essential for outgrowth of macrometastases. Therefore, EMT inhibitor alone could be counter productive in preventing distant metas tases if patients already have disseminated tumor cells in distant organs. In these cases, combining therapies targeting TME signals with traditional chemotherapy and targeted therapies to simul taneously inhibit EMT and cell proliferation could be a more powerful approach to eradicate both migrating as well as prolif erating tumor cells, thus halting tumor progression.
